Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Álvaro Narrillos-Moraza"'
Autor:
Álvaro Narrillos-Moraza, Patricia Gómez-Martínez-Sagrera, Miguel Ángel Amor-García, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina Villanueva-Bueno, Ignacio Gómez-Centurión, Ana Herranz-Alonso, María Sanjurjo-Sáez
Publikováno v:
JMIR mHealth and uHealth, Vol 10, Iss 2, p e32826 (2022)
BackgroundHematological conditions are prevalent disorders that are associated with significant comorbidities and have a major impact on patient care. Concerning new tools for the care of these patients, the number of health apps aimed at hematologic
Externí odkaz:
https://doaj.org/article/2da972dc72764be99224d7fddafc2e13
Autor:
Juan Vicente-Valor, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Sara Pérez-Ramírez, Cristina Villanueva-Bueno, Álvaro Narrillos-Moraza, Sebastián García-Sánchez, Manel Beamud-Cortés, Ana Herranz, María Sanjurjo
Publikováno v:
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Background Abiraterone and enzalutamide, androgen receptor pathway inhibitors (ARPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), are at high risk of potential drug interactions (PDIs). We aimed to describe PDIs and t
Autor:
Paula Ruiz-Briones, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Juan Vicente-Valor, Rosa Alvarez, Cristina Villanueva-Bueno, Álvaro Narrillos-Moraza, Ana Herranz, Maria Sanjurjo
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522211437
Introduction Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) indicated for the treatment of epidermal growth factor receptor mutated non-small cell lung cancer (NSCLC). It has demonstrated better results concerning effectiveness tha
Autor:
Álvaro Narrillos-Moraza, Patricia Gómez-Martínez-Sagrera, Miguel Ángel Amor-García, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina Villanueva-Bueno, Ignacio Gómez-Centurión, Ana Herranz-Alonso, María Sanjurjo-Sáez
Publikováno v:
JMIR mHealth and uHealth. 10(2)
Background Hematological conditions are prevalent disorders that are associated with significant comorbidities and have a major impact on patient care. Concerning new tools for the care of these patients, the number of health apps aimed at hematologi
Autor:
Álvaro Narrillos-Moraza, Patricia Gómez-Martínez-Sagrera, Miguel Ángel Amor-García, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina Villanueva-Bueno, Ignacio Gómez-Centurión, Ana Herranz-Alonso, María Sanjurjo-Sáez
BACKGROUND Hematological conditions are prevalent disorders that are associated with significant comorbidities and have a major impact on patient care. Concerning new tools for the care of these patients, the number of health apps aimed at hematologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21257be523f7762c09afe9660178d6ef
https://doi.org/10.2196/preprints.32826
https://doi.org/10.2196/preprints.32826